WS Investments
VC Fund
Palo Alto, United States
WS Investments is a VC fund in Palo Alto focused on Health Care and Software. WS Investment Co. is the investment fund of law firm Wilson Sonsini Goodrich & Rosati. The fund was formed in 1978 and has been managed throughout by Mario Rosati. All fundraising is internal, with mandatory participation by partners and is occasionally opened to associates. Among other investments, the fund was a pre-IPO investor in Google,Brocade (partner Larry Sonsini contributed the options he received from his post as a director), Juniper Networks and Avanex.
- Total investments:
- 58
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries WS Investments invests in
Health CareSoftwareBiotechnologyMedicalE-Commerce
Stages WS Investments invests in
SeedSeries ASeries BFunding RoundSeries C
Countries WS Investments invests in
United StatesAustralia
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Larry W. Sonsini
|
|||
Mario Rosati
|
|||
3 more contacts available
Investment Focus
Industry
- Health Care 12 (21%)
- Software 10 (17%)
- Biotechnology 6 (10%)
- Medical 5 (9%)
- E-Commerce 5 (9%)
Stage
- Seed 18 (31%)
- Series A 15 (26%)
- Series B 8 (14%)
- Funding Round 5 (9%)
- Series C 3 (5%)
Country
- United States 50 (86%)
- Australia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Larry W. Sonsini
Founder and Managing Director
|
Founder and Managing Director | Total investments: 2 | Find email | |
|
Mario Rosati
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Integral Privacy Technologies
|
Integral focuses on compliantly connecting health data in a secure and efficient manner, serving as the only end-to-end regulated insights platform transforming compliance barriers into competitive advantage. We offer a range of products and services to help businesses accelerate their data processing, collaborate securely, and unlock new insights.Our software provides robust security and privacy protections while enabling seamless collaboration with regulated data. Our flagship offering is Expert Certifications-as-a-Service, which allows companies to work with de-identified data to discover novel insights and make innovative business decisions. Unlike traditional methods conducted by consultants that take months, our automated expert certification software drastically reduces processing time to mere hours.Through our expertise in privacy-enhancing technologies and deep understanding of healthcare data complexities, we help enterprises extract bespoke, actionable insights from regulated data that aren't available anywhere else, making us a valuable asset for any company looking to compliantly work with regulated data. | $18M / Series A / Jul 01, 2026 | |
Alias Technologies
|
Alias Technologies seeks to expedite innovation by increasing the value of technological footprint. It assists enterprises in realizing their technology investment through vendor consolidation analyses, cost-cutting approaches, and industry experience. | $3M / Seed / Aug 31, 2023 | |
BriefCatch
|
BriefCatch is a legal technology company that develops an AI-enhanced writing platform to help legal professionals refine, edit, and analyze legal documents. Its software applies natural language processing and legal writing insights to provide real-time editing suggestions, tailored feedback, and stylistic improvements for briefs, motions, memos,and other legal texts, with features that include citation assistance and clarity-focused edits. The platform generates context-aware recommendations based on a proprietary rules engine grounded in authoritative legal writing practices rather than generic language models. BriefCatch integrates into existing drafting workflows to support document preparation, streamline review tasks, and reduce manual editing time. It also offers metrics and scoring tools to help users assess dimensions of their writing, such as flow, readability, and precision. The company continues to expand its capabilities with updated versions that add features like advanced citation tools and interactive writing support to further support legal drafting needs. | $3.5M / Seed / Aug 01, 2023 | |
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $6.1M / Series A / Jul 11, 2023 | |
Holocron Technologies
|
Holocron uses publicly available information to track global science and technology developments. | $1.5M / Pre-Seed / Apr 27, 2023 | |
Cloudian
|
Cloudian is a file and object storage company specializing in S3 object storage in the data center. It turns information into insight with an infinitely scalable platform that consolidates, manages, and protects enterprise data. Cloudian Enterprise Object Storage brings cloud technology and economics to the data center with uncompromising datadurability, intuitive management tools, and the industry’s most compatible S3 API.Cloudian and its ecosystem partners help Global 1000 customers simplify unstructured data management today while preparing for the data demands of AI and machine learning tomorrow. | $60M / Venture - Series Unknown / Jan 18, 2023 | |
ESN Cleer
|
ESN Cleer is committed to transforming the way we combat specific segments of Cardiomyopathy with its focus on repurposed drugs of orphan indications (rare diseases without specific drug treatments). Such detrimental diseases are some of the most significant causes of Heart Failure—an ailment that heavily impact on a large spectrum of the CVDpopulation.Such diseases or syndromes carry a high mortality risk, but it also profoundly degrades the quality of life for those affected, thus underlining the importance of ESN Cleer's mission. | $840K / Seed / Oct 02, 2022 | |
ViFiVE
|
ViFiVE is a patient app that is two weeks old. They can achieve remote therapeutic monitoring (RTM) with compliance and outcomes at their fingertips. It is a software development company that provides AI technology. An online inquiry form is available on the company's website. | Jan 01, 2022 | |
|
ViFiVE
|
ViFiVE is a patient app that is two weeks old. They can achieve remote therapeutic monitoring (RTM) with compliance and outcomes at their fingertips. It is a software development company that provides AI technology. An online inquiry form is available on the company's website. | Seed / Jan 01, 2022 | |
Crowdz
|
Crowdz is the leader in modernizing the traditional Trade Finance industry by auto risk rating assets at the receivable level. Funders can gain valuable insights to make quick decisions that match their investment strategy. Crowdz has auto risk-rated $4.2b of receivables, and funders have financed over $93m utilizing Crowdz technology. Customersand investors include Citibank, Barclays, Meta, EG Funds Management, Techstars Ventures, and Bold Capital Partners, with over $28 million in investment raised to date.Assets sold to private equity. | $3M / Series A / Jun 30, 2020 | |
| See all 58 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Marketplace Investors
40,654 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does WS Investments invest in?
WS Investments invests primarily in Health Care, Software and Biotechnology startups, most often at Seed and Series A stage. Most of the 58 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact WS Investments?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WS Investments?
The team at WS Investments includes Larry W. Sonsini (Founder and Managing Director) and Mario Rosati (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
